Mayo Clinic deploys Aiforia AI pathology platform across 84 users with 3 clinical tests in production

Mayo Clinic needed to integrate AI into its anatomic pathology workflows to elevate diagnostic capabilities and enable AI model development across pathologists with varying levels of technical expertise. The institution required a platform that could support everything from entry-level users to advanced researchers while meeting strict IT and security standards. A key challenge was ensuring a seamless path from algorithm discovery to clinical deployment.

After evaluating vendors against six criteria—approachability, modeling flexibility, collaboration support, IT/security compliance, discovery-to-deployment continuity, and scalability—Mayo Clinic selected Aiforia as its AI pathology platform. A comprehensive AI ecosystem was created with structured training, onboarding, and support resources to engage pathologists at all expertise levels. The platform supports both translational research and live clinical workflow.

84 users completed training in 2022–2023, with 30 out of 31 AI development projects progressing through annotation, training, and validation. The first clinical application, Aiforia's Ki67 AI model for breast cancer diagnostics, launched in March 2023. Three Aiforia-powered tests are now part of Mayo Clinic's diagnostic test portfolio, and 15 abstracts were submitted to national meetings including 13 to USCAP 2024.

• Democratizing AI in pathology requires platforms designed for users across the full spectrum of technical expertise, not just data scientists.
• A clear pathway from AI discovery to clinical deployment is critical — pathologists need to be able to move from model development directly into practice.
• Structured onboarding and institutional support resources dramatically reduce adoption barriers and improve AI model quality.